Socorro Asset Management Fully Liquidates ARE Stake
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2026
0mins
Should l Buy ARE?
Source: Fool
- Liquidation Transaction: According to a SEC filing dated February 17, 2026, Socorro Asset Management fully liquidated its stake in Alexandria Real Estate Equities by selling 62,346 shares, reducing its position from 1.9% to zero, indicating a cautious outlook on the company's future prospects.
- Performance Decline: As of February 18, 2026, ARE shares were priced at $54.16, down 39.8% over the past year, underperforming the S&P 500 by 52.1 percentage points, reflecting market disappointment with its biopharmaceutical-focused portfolio.
- Financial Condition: ARE reported a net loss of $1.4 billion in 2026, with funds from operations at $1.5 billion, which is 5.8% lower than in 2024, indicating a deterioration in financial health that may affect future investment attractiveness.
- Dividend Adjustment: In December 2026, ARE reduced its quarterly dividend by 45% to $0.72 per share, resulting in a current yield of 5.3%, which may undermine investor confidence seeking stable income.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 51.050
Low
41.00
Averages
56.85
High
67.00
Current: 51.050
Low
41.00
Averages
56.85
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Charitable Recognition: Alexandria Real Estate has been named one of America's Most Charitable Companies, highlighting its exceptional commitment to social responsibility and enhancing its reputation among investors and the public.
- Comprehensive Evaluation: This award was developed by Newsweek in collaboration with market research partner Statista, based on an independent survey of approximately 18,000 U.S. residents that assessed companies' philanthropic activities and social impact.
- Community Support Excellence: Alexandria's outstanding support for local and community-based organizations demonstrates its active engagement in social good beyond business interests, further solidifying its leadership position in the industry.
- Brand Image Enhancement: By receiving this honor, Alexandria Real Estate not only boosts its brand image but may also attract more investor attention, potentially driving future business growth and market expansion.
See More
- Charitable Recognition: Alexandria Real Estate has been named one of America's Most Charitable Companies by Newsweek, highlighting its exceptional commitment to social responsibility and community support, which reinforces its brand as a mission-driven company.
- Innovative Medical Collaboration: The company received the Charles A. Sanders Award from the Foundation for the National Institutes of Health, recognizing its contributions to accelerating biomedical innovation, particularly in developing a precision medicine framework for depression in collaboration with the National Institute of Mental Health and the FDA.
- Market Capitalization: As of December 31, 2025, Alexandria's market capitalization reached $20.75 billion, with an asset base of 35.9 million square feet of operating properties, demonstrating its leadership and strong asset foundation in the life science real estate sector.
- Commitment to Social Responsibility: The company is dedicated to driving community health and vitality through various social responsibility initiatives, including accelerating medical innovation, supporting military personnel and their families, and improving nutrition, showcasing its proactive role in addressing significant societal challenges.
See More
- Quarterly Dividend Announcement: Alexandria Real Estate Equities declares a quarterly dividend of $0.72 per share, consistent with previous distributions, demonstrating the company's ongoing ability to maintain stable cash flows despite market challenges.
- Stable Yield: The forward yield of 5.33% reflects the company's capacity to provide relatively attractive returns to investors in the current economic environment, thereby bolstering investor confidence.
- Shareholder Rights Assurance: The dividend will be payable on April 15, with a record date of March 31 and an ex-dividend date also on March 31, ensuring shareholders receive timely returns and further solidifying their trust in the company.
- Financing Activity Update: Alexandria Real Estate also announces a $750 million senior notes offering aimed at strengthening the company's capital structure and liquidity to address market supply-demand imbalances.
See More
- Quarterly Cash Dividend: Alexandria Real Estate Equities, Inc. has declared a quarterly cash dividend of $0.72 per common share for Q1 2026, payable on April 15, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Dividend Yield: With a dividend yield of 5.2% based on the closing stock price on February 26, 2026, this attractive yield not only draws investor interest but also enhances the company's competitive position in the market.
- Financial Flexibility: The declared dividend remains consistent with the previous quarter, reflecting the company's dedication to strengthening its robust balance sheet while enhancing financial flexibility and liquidity for effective capital utilization.
- Low Payout Ratio: The dividend payout ratio stands at a favorable 33% for the quarter ended December 31, 2025, indicating a healthy balance between dividends and funds from operations, further solidifying the company's financial health.
See More
- Complete Liquidation: Socorro Asset Management LP fully liquidated its stake in Alexandria Real Estate Equities during Q4 2025 by selling 62,346 shares, resulting in a $5.20 million decrease in position value, indicating a lack of confidence in the company.
- Declining Asset Management Proportion: Prior to liquidation, Alexandria represented 1.9% of Socorro's assets under management, and post-liquidation, Socorro holds no ARE shares, reflecting a strategic shift in its investment approach towards the REIT.
- Poor Financial Performance: Alexandria reported a net loss of $1.4 billion in 2026, despite funds from operations at $1.5 billion, which was a 5.8% decline from 2024, highlighting underperformance in its biopharmaceutical-focused real estate portfolio.
- Significant Dividend Cut: Alexandria reduced its quarterly dividend by 45% to $0.72 per share in December, resulting in a current yield of 5.3%, which may negatively impact investor confidence and future capital inflows.
See More
- Liquidation Transaction: According to a SEC filing dated February 17, 2026, Socorro Asset Management fully liquidated its stake in Alexandria Real Estate Equities by selling 62,346 shares, reducing its position from 1.9% to zero, indicating a cautious outlook on the company's future prospects.
- Performance Decline: As of February 18, 2026, ARE shares were priced at $54.16, down 39.8% over the past year, underperforming the S&P 500 by 52.1 percentage points, reflecting market disappointment with its biopharmaceutical-focused portfolio.
- Financial Condition: ARE reported a net loss of $1.4 billion in 2026, with funds from operations at $1.5 billion, which is 5.8% lower than in 2024, indicating a deterioration in financial health that may affect future investment attractiveness.
- Dividend Adjustment: In December 2026, ARE reduced its quarterly dividend by 45% to $0.72 per share, resulting in a current yield of 5.3%, which may undermine investor confidence seeking stable income.
See More









